Novo Nordisk A/S (NVO)
| Market Cap | 194.29B |
| Revenue (ttm) | 20.14B |
| Net Income (ttm) | 6.80B |
| Shares Out | 2.30B |
| EPS (ttm) | 3.01 |
| PE Ratio | 28.05 |
| Forward PE | 26.81 |
| Dividend | $9.10 |
| Dividend Yield | 10.78% |
| Trading Day | June 11 |
| Last Price | $84.45 |
| Previous Close | $84.76 |
| Change ($) | -0.31 |
| Change (%) | -0.37% |
| Day's Open | 84.26 |
| Day's Range | 83.86 - 84.49 |
| Day's Volume | 789,086 |
| 52-Week Range | 61.90 - 84.94 |
Novo Nordisk's (NVO) GLP-1 product, semaglutide gets FDA approval for weight loss in people living with obesity. It will be marketed by the brand name of Wegovy.
Novo Nordisk A/S (NYSE: NVO) has gained U.S. approval for a once-weekly semaglutide 2.4 mg injection, dubbed Wegovy, for chronic weight management. The drug will be available to obese adults and certain...
Bagsværd, Denmark, 7 June 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 Ap...
Novo Nordisk (NVO) inks an exclusive license agreement with Heartseed Inc. to manufacture and commercialize the latter's HS-001, a cell therapy developed for the treatment of heart failure.
Novo Nordisk A/S (NYSE: NVO) has resubmitted a label expansion application to FDA for Ozempic (semaglutide) to introduce a new dose of 2.0 mg. Semaglutide is a glucagon-like peptide-1 (GLP-1) analog.
Bagsværd, Denmark, 28 M ay 202 1 – Novo Nordisk today announced the resubmission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation fo...
Novo Nordisk A/S – Share repurchase programme
This stock could be a great addition to any long-term portfolio.
Novo Nordisk AS ( NVO , Financial) and Eli Lilly and Co. ( LLY , Financial) are testing unique weight-loss drugs aimed at tackling the growing problem of obesity and beefing up the top and bottom lines ...
Bagsværd, Denmark, 7 May 202 1 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 2,586 million from Novo Holdings A/S. This transaction ...
Which diabetes drug maker will win this photo finish for investors?
Novo Nordisk (NVO) beat estimates for both earnings and sales in the first quarter of 2021.
Growth is coming back following Covid-19, Novo Nordisk CEO says
Novo Nordisk CEO Lars Fruergaard Jørgensen discusses first-quarter earnings and the outlook for the North American region for the Danish pharmaceutical company.
Denmark's Novo Nordisk A/S (NYSE: NVO) raised its financial forecast after reporting strong first-quarter sales and earnings. The company says the sales were still hit by the effect of patients and whol...
Denmark's Novo Nordisk, the world's biggest manufacturer of diabetes drugs, raised its financial forecast in local currencies on Wednesday after reporting first quarter sales and earnings above expectat...
Bagsværd, Denmark, 4 May 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 1...
Novo Nordisk's Articles of Association 2021
Bagsværd , Denmark, 27 April 2021 – At Novo Nordisk's Annual General Meeting on 25 March 2021, it was decided to reduce the company's B share capital from DKK 362,512,800 to DKK 354,512,800 by cancellat...
Novo Nordisk (NVO) to start a phase IIIa study testing oral semaglutide 50 mg in people with obesity or those who are overweight with comorbidities. The study is expected to begin in second-half 2021.
Novo Nordisk A/S (NYSE: NVO) is entering the Phase 3a study in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a trial with once-weekly subcutaneously adminis...
Bagsværd , De n mark, 21 April 2021 – Novo Nordisk today announced the decision to enter phase 3a development in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phas...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
NAIROBI, Kenya--(BUSINESS WIRE)-- #bestplacestowork--Novo Nordisk Kenya, an affiliate of the global healthcare company with more than 90 years of innovation and leadership in diabetes care, has been rec...
Considering business quality is the best way to earn growing payouts over time.
Correction due to missing pdf-file.
Bagsværd, Denmark, 25 March 2021 - Today, Novo Nordisk A/S held its Annual General Meeting.
The FDA has issued a Refusal to File letter covering Novo Nordisk A/S' (NYSE: NVO) label expansion application for once-weekly semaglutide 2.0 mg to treat type 2 diabetes, which was filed on 20 January....
Bagsværd, Denmark, 22 March 2021 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Refusal to File letter covering the label expansion application for once-weekl...
Gilead (GILD) expands collaboration with Novo Nordisk for developing NASH treatments.
Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.
Gilead Sciences Inc (NASDAQ: GILD) and Novo Nordisk A/S (NYSE: NVO) have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). The companies will conduct a Phase 2b study of Nov...
Bagsværd, Denmark, 23 February 2021 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 25 March 2021 at 14:00 (CET)
Bagsværd, Denmark, 17 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accord...
Bagsværd, Denmark, 12 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accord...
Bagsværd, Denmark, 10 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accord...
Health care: Novo Nordisk CEO discusses 7% sales growth in 2020 and overall industry
Yahoo Finance's Brian Sozzi, Julie Hyman, and Myles Udland speak with Novo Nordisk CEO Lars Jørgensen about the company's healthcare treatments and outlook. #healthcare Subscribe to Yahoo Finance: https...
Bagsværd, Denmark, 5 February 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...
Novo Nordisk (NVO) beats both earnings and sales estimates for the fourth quarter of 2020.
Shares of Novo Nordisk (NYSE:NVO) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 14.29% year over year to $0.64, which were in line with the estimate of ...
Financial report for the period 1 January 2020 to 31 December 2020
Bagsværd, Denmark, 2 February 2021 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Novo Nordisk (NVO) submits a label expansion application to the FDA for the existing marketing authorization for Ozempic to include a new dose of 2.0 mg.
Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation fo...
Novo Nordisk is the global leader in obesity and diabetes treatments. There is evidence that the lockdowns increased the number of people suffering from obesity.
Novo Nordisk is a well-managed business with long-term growth opportunities. It is the world market leader in diabetes and obesity care.
Novo Nordisk A/S (NVO) CEO Lars Jørgensen Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
PLAINSBORO, N.J., Jan. 4, 2021 /PRNewswire/ -- Today, Novo Nordisk announced the extension of its COVID-19 Patient Assistance Program until June 30, 2021, for those who have lost health insurance covera...
About NVO
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration a... [Read more...]
| Industry Biotechnology | Founded 1923 |
| CEO Lars Fruergaard Joergensen | Employees 45,157 |
| Stock Exchange NYSE | Ticker Symbol NVO |
Financial Performance
In 2020, NVO's revenue was 126.95 billion, an increase of 4.04% compared to the previous year's 122.02 billion. Earnings were 42.14 billion, an increase of 8.18%.
Analyst Forecasts
According to 3 analysts, the average rating for NVO stock is "Hold." The 12-month stock price forecast is 80.59, which is a decrease of -4.57% from the latest price.